



US009249218B2

(12) **United States Patent**
Basey et al.

(10) **Patent No.:** US 9,249,218 B2
(45) **Date of Patent:** *Feb. 2, 2016

(54) **PROTEIN PURIFICATION**(75) Inventors: **Carol D. Basey**, Winters, CA (US);
Greg S. Blank, Menlo Park, CA (US)(73) Assignee: **GENENTECH, INC.**, South San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 214 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 13/313,931

(22) Filed: **Dec. 7, 2011**(65) **Prior Publication Data**

US 2014/0018523 A1 Jan. 16, 2014

Related U.S. Application Data

(60) Continuation of application No. 12/418,905, filed on Apr. 6, 2009, now abandoned, which is a continuation of application No. 11/398,447, filed on Apr. 5, 2006, now Pat. No. 7,531,645, which is a continuation of application No. 10/949,683, filed on Sep. 24, 2004, now Pat. No. 7,074,404, which is a continuation of application No. 10/253,366, filed on Sep. 24, 2002, now abandoned, which is a division of application No. 09/304,465, filed on May 3, 1999, now Pat. No. 6,489,447.

(60) Provisional application No. 60/084,459, filed on May 6, 1998.

(51) **Int. Cl.**

<i>A61K 39/395</i>	(2006.01)
<i>A61K 39/00</i>	(2006.01)
<i>A61K 39/40</i>	(2006.01)
<i>C07K 16/28</i>	(2006.01)
<i>C07K 1/18</i>	(2006.01)
<i>C07K 16/06</i>	(2006.01)
<i>C07K 16/32</i>	(2006.01)
<i>A61K 38/00</i>	(2006.01)

(52) **U.S. Cl.**

CPC	<i>C07K 16/2863</i> (2013.01); <i>C07K 1/18</i> (2013.01); <i>C07K 16/065</i> (2013.01); <i>C07K 16/32</i> (2013.01); <i>A61K 38/00</i> (2013.01); <i>C07K 2317/24</i> (2013.01); <i>C07K 2317/56</i> (2013.01)
-----------	---

(58) **Field of Classification Search**USPC 424/130.1, 133.1, 138.1, 141.1, 152.1
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

4,753,894 A	6/1988	Frankel et al.
4,966,851 A	10/1990	Durance et al.
5,110,913 A	5/1992	Coan et al.
5,112,951 A	5/1992	Beidler et al.
5,115,101 A	5/1992	Bloom et al.
5,118,796 A	6/1992	Prior et al.

5,169,774 A	12/1992	Frankel et al.
5,196,323 A	3/1993	Bodo et al.
5,256,769 A	10/1993	Kato et al.
5,279,823 A	1/1994	Frenz et al.
5,429,746 A	7/1995	Shadle et al.
5,451,662 A	9/1995	Naveh et al.
5,525,338 A	6/1996	Goldenberg
5,677,171 A	10/1997	Hudziak et al.
5,821,337 A	10/1998	Carter et al.
6,005,081 A	12/1999	Burton et al.
6,054,561 A	4/2000	Ring
6,127,526 A	10/2000	Blank
6,267,958 B1	7/2001	Andya et al.
6,339,142 B1	1/2002	Basey et al.
6,399,333 B1	6/2002	Burg et al.
6,417,335 B1	7/2002	Basey et al.
6,489,447 B1	12/2002	Basey et al.
7,074,404 B2 *	7/2006	Basey et al. 424/133.1
2009/0220492 A1	9/2009	Basey et al.

FOREIGN PATENT DOCUMENTS

EP	333574	9/1989
EP	556083	8/1993
EP	460426 B1	9/1997
EP	1075488	5/1998
EP	289129 A2	11/1998
EP	1075488	5/2003
WO	WO 89/05157	6/1989
WO	WO 92/22653	12/1992
WO	WO 93/06217	4/1993
WO	WO 94/22905	10/1994
WO	WO 95/22389	8/1995
WO	WO 96/33208	10/1996
WO	WO 96/40883	12/1996
WO	WO 97/04801	2/1997

(Continued)

OTHER PUBLICATIONS

Adachi, et al., "Ion-exchange high-performance liquid chromatographic separation of protein isoforms on MCI GEL ProtEx stationary phases", Journal of Chromatograph, 763(1-2): 57-63 (1997).
Cacia, et al., "Protein sorting by high-performance liquid chromatography, I. Biomimetic chromatography of recombinant human deoxyribonuclease I on polyionic stationary phases" J. Chromatography—634: 229-239, (1993).

Carter, et al, "Humanization of an Anti-p185HLR⁴ Antibody for Human Cancer Therapy", Proc. Natl. Acad. Sci. USA 89(10): 4285-4289, (1992).

Cole, et al, "Cysteine proteinase inhibitors of the canine intervertebral disc" Biochimica et Biophysica Acta—952(21): 201-207, (1988).

Eigenbrot, et al, "X-Ray Structures of the Antigen-Binding Domains Anti-p185HER² Antibody 4D5 and Comparison With Molecular Modeling" J. MoL Biol.—229: 969-995, (1993).

Emea, "Scientific Discussion" (Module reflecting the scientific discussion for the approval of Herceptin by the European Medicines Agency (<http://www.emea.eu.int/humandocs/Humans/EPAR/herceptin/herceptin.htm>), pp. 1-42 (2005).

(Continued)

Primary Examiner — Rodney P Swartz

(74) Attorney, Agent, or Firm — Diane Marschang; Ginger R. Dreger; Arnold & Porter LLP

ABSTRACT

A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.

7 Claims, 7 Drawing Sheets